http://www.markskousen.com/visitor.php?offer=10508

You Get the Opportunity to Make 4 Times
Your Money in Just 9 Months

Here's How. . .
Dear Investor,
I have a stock that I'm dying to put in my personal portfolio. But I can't...

It's a medical technology company that is currently experiencing blockbuster revenue growth.

Sales, which have raced past $100 million over the last twelve months, are growing at 48% per quarter. (That's right, per quarter!) Earnings, too, are blowing past estimates.

But this is just the beginning. For reasons I'm about to explain, this firm's profits are likely to hit the moon in the weeks ahead. And so are its shares.

That's because the company I'm talking about is not just a gangbuster growth stock. It's also a highly attractive takeover candidate.

I'm convinced this firm is likely to be bought out -- at an enormous premium -- before this year's fabulous earnings even materialize. Shareholders, of course, stand to make a fortune in the process...

With all this upside potential, you might ask, why don't I own this stock already? Quite simply, because it wouldn't be right for me to pile into this stock, and tell all my pals on Wall Street about it, without giving my readers a chance to pick it up first.

In the meantime, I'm about to burst at the seams...

In my more than 30 years in the investment advisory business, I've never seen an investment opportunity with greater short-term profit potential than this one.

Having done the research and due diligence on this special situation, I believe this company's shares will quadruple over the next nine months.

The beautiful part is this medical company has a virtual moat built around its profit margins. That's because the firm is part of a duopoly.

(A monopoly, of course, is when there is only one provider of a particular product or service. A duopoly is when there are just two providers.)

The company I'm recommending is the smaller of the two. In fact, it is less than 1/30th the size of its sole competitor. Yet scientists, engineers and medical technicians worldwide have already weighed in. The smaller company has the far superior technology...

That means this medical company is about to eat its competitor's lunch. Either that or the larger company -- or one of its rivals -- will buy it out entirely. Why? To acquire its cutting edge technology... and eliminate the competitive threat.

Needless to say, a takeover announcement would cause our shares to skyrocket... instantly. (That's why giants like Johnson & Johnson and Medtronic have already invested millions in shares of this company.)

I look at it this way. "Heads," we get phenomenal earnings growth. "Tails," a sudden takeover bid materializes. Either way, a potential jackpot lies just ahead for shareholders.

Investors stand to make at least four times their money over the next nine months.

Here's how to become one of them...

The One Stock You Need to Own Today

Before we get started, please understand this is a highly unusual situation.

The medical sector can be one of the trickiest sectors for investors. Most companies face not only murderous competition in the race to innovate, but also a long and expensive process of clinical trials, product patenting and FDA approval that takes years to complete.

The result? Most companies don't make it past the "start-up" phase. It takes more than a promising technology or wishful thinking to make a great medical stock.

What it does take is an almost perfect combination of the following: ..............................................................

Mark Skousen, Ph.D
Editor, Forecasts & Strategies
===================================================================================
===================================================================================
My guess is VOLC
1. Made a search on google for ""functional measurement" (FM) devices ".
2. From seeking alpha,
"Volcano (VOLC), Boston Scientific (BSX), Johnson & Johnson (JNJ), and General Electric (GE)
A great way to play fears over drug-coated stents is to buy Volcano, a company that makes intravascular ultrasound catheters which examine the inside of arteries, according to Cramer. Although this technology is not new, it has been underused until the recent stent controversy. Volcano's largest rival is BSX, which Cramer calls "the Citigroup of healthcare" and Volcano has partnerships with JNJ and GE. "
3. http://finance.yahoo.com/q/ks?s=VOLC
revenue: 112.75M
Qtrly Revenue Growth (yoy): 48.80%
===================================================================================

Good research, tom76. Only thing that bothers me about this company is the large number of insider sales over the past six months. Not that that means a whole lot...could be just profit taking.